Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs

Detalhes bibliográficos
Autor(a) principal: Santos, Adriana O.
Data de Publicação: 2020
Outros Autores: Pires, Patrícia C., Rodrigues, Márcio, Alves, Gilberto, Santos, Liliana T.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.6/10489
Resumo: Intranasal administration could increase both safety and efficacy of drugs acting on the central nervous system, but low solubility severely limits administration through this route. Phenytoin’s prodrug, fosphenytoin, is hydrophilic and freely soluble in water, but less permeable since it is dianionic. We aimed to assess whether this phosphoester prodrug could be a suitable alternative to phenytoin in intranasal delivery. Secondly, we aimed to compare simple formulation strategies in fosphenytoin delivery. Fosphenytoin formulations containing thermosensitive and/or mucoadhesive (hydroxypropyl methylcellulose, HPMC) polymers were developed, guided by viscosity, gelling temperatures, osmolality, and in vitro drug release tests. Then, a pharmacokinetic study was performed, comparing an intravenous fosphenytoin solution, an intranasal fosphenytoin solution, and intranasal fosphenytoin mucoadhesive formulations with or without albumin. Formulations containing HPMC allowed high drug strengths, and had a relatively fast release profile, which was not changed by albumin. Intranasal administration of a formulation with HPMC and albumin prolonged drug concentration over time and led to complete or even increased absolute bioavailability. Moreover, phenytoin’s blood levels did not reach the high peak obtained with intravenous administration. In conclusion, the use of phosphate ester prodrugs could be an efficient and safe strategy to increase the intranasal bioavailability of poorly soluble drugs.
id RCAP_bccab7ffe114bbbe377a3739125af765
oai_identifier_str oai:ubibliorum.ubi.pt:10400.6/10489
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugsAlbuminBrain deliveryEpilepsyFosphenytoinIntranasalPharmacokineticsIntranasal administration could increase both safety and efficacy of drugs acting on the central nervous system, but low solubility severely limits administration through this route. Phenytoin’s prodrug, fosphenytoin, is hydrophilic and freely soluble in water, but less permeable since it is dianionic. We aimed to assess whether this phosphoester prodrug could be a suitable alternative to phenytoin in intranasal delivery. Secondly, we aimed to compare simple formulation strategies in fosphenytoin delivery. Fosphenytoin formulations containing thermosensitive and/or mucoadhesive (hydroxypropyl methylcellulose, HPMC) polymers were developed, guided by viscosity, gelling temperatures, osmolality, and in vitro drug release tests. Then, a pharmacokinetic study was performed, comparing an intravenous fosphenytoin solution, an intranasal fosphenytoin solution, and intranasal fosphenytoin mucoadhesive formulations with or without albumin. Formulations containing HPMC allowed high drug strengths, and had a relatively fast release profile, which was not changed by albumin. Intranasal administration of a formulation with HPMC and albumin prolonged drug concentration over time and led to complete or even increased absolute bioavailability. Moreover, phenytoin’s blood levels did not reach the high peak obtained with intravenous administration. In conclusion, the use of phosphate ester prodrugs could be an efficient and safe strategy to increase the intranasal bioavailability of poorly soluble drugs.European Regional Development funds through the Operational Programme “Centro 2020”, through the ICON project (Interdisciplinary Challenges On Neurodegeneration, reference CENTRO-01-0145-FEDER-000013).ElsevieruBibliorumSantos, Adriana O.Pires, Patrícia C.Rodrigues, MárcioAlves, GilbertoSantos, Liliana T.2020-11-04T12:23:32Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.6/10489engPires, P. C., Santos, L., Rodrigues, M., Alves, G., & Santos, A. O. Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs. International Journal of Pharmaceutics. Accepted for publication 2020/10/29. Ref. No.: IJP-D-20-01688R1https://doi.org/10.1016/j.ijpharm.2020.120040info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-15T09:52:22Zoai:ubibliorum.ubi.pt:10400.6/10489Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:50:25.953674Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs
title Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs
spellingShingle Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs
Santos, Adriana O.
Albumin
Brain delivery
Epilepsy
Fosphenytoin
Intranasal
Pharmacokinetics
title_short Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs
title_full Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs
title_fullStr Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs
title_full_unstemmed Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs
title_sort Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs
author Santos, Adriana O.
author_facet Santos, Adriana O.
Pires, Patrícia C.
Rodrigues, Márcio
Alves, Gilberto
Santos, Liliana T.
author_role author
author2 Pires, Patrícia C.
Rodrigues, Márcio
Alves, Gilberto
Santos, Liliana T.
author2_role author
author
author
author
dc.contributor.none.fl_str_mv uBibliorum
dc.contributor.author.fl_str_mv Santos, Adriana O.
Pires, Patrícia C.
Rodrigues, Márcio
Alves, Gilberto
Santos, Liliana T.
dc.subject.por.fl_str_mv Albumin
Brain delivery
Epilepsy
Fosphenytoin
Intranasal
Pharmacokinetics
topic Albumin
Brain delivery
Epilepsy
Fosphenytoin
Intranasal
Pharmacokinetics
description Intranasal administration could increase both safety and efficacy of drugs acting on the central nervous system, but low solubility severely limits administration through this route. Phenytoin’s prodrug, fosphenytoin, is hydrophilic and freely soluble in water, but less permeable since it is dianionic. We aimed to assess whether this phosphoester prodrug could be a suitable alternative to phenytoin in intranasal delivery. Secondly, we aimed to compare simple formulation strategies in fosphenytoin delivery. Fosphenytoin formulations containing thermosensitive and/or mucoadhesive (hydroxypropyl methylcellulose, HPMC) polymers were developed, guided by viscosity, gelling temperatures, osmolality, and in vitro drug release tests. Then, a pharmacokinetic study was performed, comparing an intravenous fosphenytoin solution, an intranasal fosphenytoin solution, and intranasal fosphenytoin mucoadhesive formulations with or without albumin. Formulations containing HPMC allowed high drug strengths, and had a relatively fast release profile, which was not changed by albumin. Intranasal administration of a formulation with HPMC and albumin prolonged drug concentration over time and led to complete or even increased absolute bioavailability. Moreover, phenytoin’s blood levels did not reach the high peak obtained with intravenous administration. In conclusion, the use of phosphate ester prodrugs could be an efficient and safe strategy to increase the intranasal bioavailability of poorly soluble drugs.
publishDate 2020
dc.date.none.fl_str_mv 2020-11-04T12:23:32Z
2020
2020-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.6/10489
url http://hdl.handle.net/10400.6/10489
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Pires, P. C., Santos, L., Rodrigues, M., Alves, G., & Santos, A. O. Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs. International Journal of Pharmaceutics. Accepted for publication 2020/10/29. Ref. No.: IJP-D-20-01688R1
https://doi.org/10.1016/j.ijpharm.2020.120040
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136394696720384